IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

669.01 29.54 −4.23%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. (IDXX) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
CAG 3,953 91.86%
Water segment revenue 201 4.67%
LPD 132 3.06%
Gross margin 61.80%
Operating margin 31.60%
Pre-tax margin 30.77%

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
Product revenue 2,539 2,248 2,090 1,929 1,875 1,587 1,423 1,323 1,176 1,071
Service revenue 1,764 1,649 1,571 1,439 1,340 1,120 984 891 793 704
Revenue 4,304 3,898 3,661 3,367 3,215 2,707 2,407 2,213 1,969 1,775

Gross profit by product or service $m, and margin

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009
CAG 3,953 3,574 3,352 3,059 2,890 2,386 2,119 1,935 1,703 1,523 1,356 1,223 1,140 1,072 1,000 906 843
Water segment revenue 201 185 168 156 147 129 133 125 114 104 97 95 88 85 82 77 73
LPD 132 122 122 123 136 146 133 131 128 126 127 141 124 111 114 81 77
Other segment revenue — — — — 43 46 22 22 23 23 22 27 25 25 23 40 38
Cag Lpd Segment Transition — — — — — — — — — — — 14 10 — — — —
Other, not broken out — — 19 30 — — — — — — — — — — — — —
Eliminations — — — — — — — — — — — (14) (10) — — — —
Revenue 4,304 3,898 3,661 3,367 3,215 2,707 2,407 2,213 1,969 1,775 1,602 1,486 1,377 1,293 1,219 1,103 1,032

Operating income by segment $m, and margin

Operating figures as reported in each quarter’s results release or filing

Figure Quarter Latest A year before Change
Days sales outstanding Q3 FY2026 46.70 46.50 +0.43%
Global premium instrument installed base growth Q3 FY2026 11.0% — —
IDEXX inVue Dx placements Q3 FY2026 1.9K 1.7K +11.76%
Inventory turns Q3 FY2026 1.5× 1.5× 0.00%

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.